SEC Tracker
Get the app

Mirum Pharmaceuticals MIRM

Mirum Pharmaceuticals announces positive Phase 3 trial results

Form
8-K
Filed
Importance
Routine
  1. Phase 3 EXPAND study met primary endpoint with 0.98-point improvement in pruritus (p=0.0004)
  2. 70.1% reduction in serum bile acids with maralixibat vs. 3.5% with placebo (p<0.0001)
  3. Study included 52 patients, 46 pediatric and 6 adult
  4. Company plans to submit a supplemental NDA in 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Mirum Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Acadia Pharmaceuticals ACAD public float $2.3B, Jun 30, 2025
  2. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  3. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Cytokinetics CYTK public float $2.5B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.